Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 15,304 as of Thursday, May 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 979 issues advancing vs. 1,985 declining with 110 unchanged. The Health Services industry currently sits up 0.2% versus the S&P 500, which is down 0.37. Top gainers within the industry include CareFusion ( CFN), up 0.9%, and Fresenius Medical Care AG & Co. KGaA ( FMS), up 0.8%. On the negative front, top decliners within the industry include Agilent Technologies ( A), down 1.34, and Varian Medical Systems ( VAR), down 1.29. TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today: 5. Quest Diagnostics ( DGX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Quest Diagnostics is up $0.54 (0.88) to $61.66 on average volume Thus far, 539,375 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $60.69-$61.83 after having opened the day at $60.70 as compared to the previous trading day's close of $61.12. Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $9.7 billion and is part of the health care sector. The company has a P/E ratio of 16.7, below the S&P 500 P/E ratio of 17.7. Shares are up 4.9% year to date as of the close of trading on Wednesday. Currently there is 1 analyst that rates Quest Diagnostics a buy, 2 analysts rate it a sell, and 13 rate it a hold. TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Quest Diagnostics Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.